Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas
Overview of attention for article published in Journal of Clinical Oncology, September 2013
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (89th percentile)
-
Above-average Attention Score compared to outputs of the same age and source (60th percentile)
Mentioned by
- 13 X users
- patent
- 15 patents
- wikipedia
- 2 Wikipedia pages
- f1000
- 1 research highlight platform
Readers on
- mendeley
- 146 Mendeley
- citeulike
- 1 CiteULike